Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Dana-Farber Cancer Institute Clear all
Completed Phase 1 Interventional

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

NCT04634435
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Combination Product
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

NCT02658279
View directory record Official record
Conditions
Glioma, Recurrent Malignant Glioma
Interventions
Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

NCT03661723
View directory record Official record
Conditions
Glioblastoma
Interventions
Pembrolizumab, Bevacizumab, Re-irradiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Digitally Enhanced Smoking Cessation for High Risk Smokers

NCT04691297
View directory record Official record
Conditions
Smoking, Smoking Cessation, Lung Cancer Screening, Smoking, Tobacco, Smoking Behaviors
Interventions
Escape, Standard Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
55 Years to 77 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT00136461
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
All-trans retinoic acid, Bryostatin 1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

BKM120 For Triple Negative Breast Cancer

NCT01790932
View directory record Official record
Conditions
Breast Cancer
Interventions
BKM120
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

NCT00003966
View directory record Official record
Conditions
Veno-occlusive Disease
Interventions
defibrotide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005627
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus

NCT00476086
View directory record Official record
Conditions
Mixed Mullerian Tumors of the Uterus
Interventions
Gemcitabine, Oxaliplatin, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Results available

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

NCT03993210
View directory record Official record
Conditions
Gynecologic Tumor
Interventions
Magnetic Resonance Fingerprinting (MRF), Q-space Trajectory Imaging (QTI), Magnetic Resonance Imaging Machine (MRI)
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jul 23, 2026, 8:14 PM EDT
Not yet recruiting Phase 2 Interventional

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

NCT07513324
View directory record Official record
Conditions
HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Pembroluzimab, Observation
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Prolonged Daily Temozolomide for Low-Grade Glioma

NCT00165360
View directory record Official record
Conditions
Glioma, Astrocytoma, Oligodendroglioma
Interventions
Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional Results available

Melatonin Versus Placebo in Breast Cancer

NCT01805089
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin 3 mg
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Improving Informed Consent for Palliative Chemotherapy

NCT02282722
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions
Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

NCT04660422
View directory record Official record
Conditions
Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills, Advance Directives, Natural Language Processing, Covid19
Interventions
VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:, Medical Record Review
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
42,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

NCT03139331
View directory record Official record
Conditions
Sarcoma, Refractory Sarcoma
Interventions
Pazopanib, Irinotecan, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 1 Interventional Results available

Methylphenidate for Cancer-Related Fatigue

NCT01164956
View directory record Official record
Conditions
Cancer
Interventions
methylphenidate, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
7 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

NCT03130439
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

STAMP+CBT mHealth for Cancer Pain

NCT05403801
View directory record Official record
Conditions
Active Cancer, Active Cancer Treatment, Advanced Cancer, Palliative Care, Chronic Pain Due to Cancer
Interventions
STAMP+CBT application
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Methuen, Massachusetts • Londonderry, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00165477
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Malignant Gliomas
Interventions
lenalidomide, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Jul 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib + Venetoclax in Untreated WM

NCT04273139
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
Interventions
IBRUTINIB, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Amifostine for Head and Neck Irradiation in Lymphoma

NCT00136474
View directory record Official record
Conditions
Lymphoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Amifostine, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
35 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 1 Interventional

GVAX Plus Checkpoint Blockade in Neuroblastoma

NCT04239040
View directory record Official record
Conditions
Neuroblastoma, Pediatric Solid Tumor
Interventions
Tissue collection, GVAX vaccine, Nivolumab, Ipilimumab
Procedure · Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Computerized Assessment for Patients With Cancer

NCT00852852
View directory record Official record
Conditions
Cancer
Interventions
Electronic Self-Report Assessment - Cancer (ESRA-C)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jul 23, 2026, 8:14 PM EDT